Thanks, Robyn, and good morning. This quarter was marked by strong performance and several key achievements in our portfolio management and origination efforts. I'll start my remarks with a brief overview of results and the spin-off then turn to portfolio management and origination followed by commentary on the state of the industry and capital markets before concluding. For the second quarter, AFC generated distributable earnings of $0.56 per basic weighted average share of common stock. As a reminder, distributable earnings is the primary metric the Board of Directors considers when declaring AFC's quarterly dividend. The Board declared the fifth consecutive $0.48 dividend, which was paid on July 15, 2024, to shareholders of record as of June 24, 2024. Also, in connection with the spin-off, the Board declared a special dividend of $0.15, which was paid on July 15, 2024, to shareholders of record as of July 8, 2024. Since going public, we have generated distributable earnings that met or exceeded our dividend each quarter and paid out $6.65 in dividends per share. Going forward, the Board of Directors plans to continue to declare quarterly dividends on its normal cadence. When I joined AFC last November, I said that my three key priorities were to: one, reduce exposure to underperforming credits through active portfolio management; two, to reinvigorate the origination engine; and three, to enhance our underwriting. Since then, we've made significant progress on each priority, highlighted by a successful quarter with several notable loan exits. I'm extremely pleased to announce that in June we successfully exited our largest credit facility, an $84 million loan to a subsidiary of Public Company H. During our last earnings call, we highlighted that the borrower failed to make its April interest payment in May. Less than one month later we sold the loan to a third party at par plus accrued, including default interest. This outcome was the result of months of very active portfolio management by the AFC team and generated at 19.9% internal rate of return over the life of the loan. This exit underscores our commitment to generating strong returns for our shareholders and taking a hands-on approach to managing complex credits. I'm also excited to report that in May, Private Company C made a final prepayment on its $24 million loan via excess cash flow sweeps with the last $3.5 million prepaid this past quarter. This exit generated an impressive 25.5% IRR over the life of the loan. Additionally, in prior quarters, we noted that Private Company B was in receivership following the $19 million loan maturing in September 2023. We are pleased to announce that in June, we sold our loan at par plus accrued, including exit fees. Concurrent with the sale, we provided a $15 million loan to the purchasers to finance a portion of the acquisition secured by the same collateral. Our current portfolio has a weighted average yield to maturity of 19%. And as you can see from these two exits, we have recently generated an IRR at or above the weighted average yield to maturity on certain credit facilities. We will look to redeploy this capital into solid credits at attractive yields while also further diversifying our portfolio. As of June 30, 2024, we had $1.94 per share in unrealized losses in CECL reserves. The positions we exited this quarter had CECL reserves and unrealized losses of $0.29 per share associated with them. By selling these positions at par, the $0.29 per share of reserves and unrealized losses were added back to book value. We believe we are appropriately reserved today. And while we have generated positive outcomes to date, we will continue to be laser-focused on actively managing the portfolio to unlock additional value for our shareholders. Subsidiary of Private Company G continues to make steady progress. Since we entered into the forbearance agreement in March 2024, the borrower has infused $3 million of additional equity capital and has paid over $3.9 million of interest to AFC. Additionally, there is significant accrued interest on this loan, which if paid in cash could enhance our returns. With the experienced operators we have put in place we continue to see improved performance at the borrowers, Pennsylvania and New Jersey operations. In just over three months, the New Jersey cultivation facility has gone from less than 25% planted without CO2 to fully planted with CO2 fully operational and we expect the lab and kitchen to be online sometime in the fourth quarter. As a result, we expect a significant uptick in biomass produced in one of the tightest wholesale markets in the country. Similarly, in Pennsylvania, the operating partner has driven a remarkable turnaround in the stores with sales tripling from the bottom. We are very happy with the progress so far. And expect New Jersey wholesale to be firing on all cylinders by the end of the year. On the origination front, we are making substantial progress towards our target of $100 million for 2024 and are confident in meeting or exceeding this target. Year-to-date, we have closed three deals totaling $57.3 million with two additional deals in documentation, which would bring us close to our $100 million target. Our current cannabis pipeline is steadily growing and stands at $346 million. During the quarter, we were pleased to provide a senior secured credit facility to Private Company O, one of the leading brands in the edible space. We are excited to support their growth as they expand further into the East Coast and Midwest. This transaction demonstrates our ability to provide flexible and tailored financing solutions to meet the unique requirements of our borrowers at all stages of their growth. I'd now like to provide some commentary on the industry before concluding my remarks. The march toward legalization continued yesterday with the launch of adult-use sales in Ohio. Ohio was a $500 million medical market with a very low medical patient penetration. Pennsylvania has a similar population with a medical program more than triple in size at $1.5 billion. As a result of this low penetration, we expect to see a strong flip for existing players, including a few of our borrowers. The start of AU sales in Ohio, the potential for Florida and Pennsylvania to flip in the next two years and the start-up of de novo medical programs in Alabama and Kentucky, drive our optimism around the industry growth and more importantly, the increasing demand for capital over the coming years. Turning to the capital markets. Two large – large Tier 2 public companies recently refinanced existing term loans each at an all-in yield of a little over 14%. One of these borrowers refinanced 2021 vintage debt at a 9.8% yield resulting in a 400 basis point increase in the spread versus where debt was raised in 2021. This increase in yields is in part due to industry performance since 2021, but is also due to the increase in rates generally over the past two years. All else being equal, if larger public companies are issuing at 14%, then private companies should have wider yields. With that said, we are happy with the returns we generate and are going to focus on moving up the quality curve while still targeting mid to high teens IRRs as opposed to reaching on yield. Between these refinancings, adult-use in medical expansions and the recent uptick in M&A activity, we expect demand for debt capital to remain robust and the supply demand imbalance for that capital to persist. With the spin-off of our commercial real estate business, we are now fully focused on lending to the cannabis industry. We remain confident in our ability to continue to deliver strong financial performance and generate value for our shareholders. We are well positioned to capitalize on the growing opportunities in the industry and believe the capital supply demand imbalance will allow us to deliver attractive risk-adjusted returns. With that, I'll turn it over to Brandon to discuss our financial results in more detail.